Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir

Gastroenterology

Volumn 152, Issue 3, 2017, Pages 586-597

  Komatsu, Takashi E ^a   Boyd, Sarita ^a   Sherwat, Adam ^a   Tracy, LaRee ^a   Naeger, Lisa K ^a   O'Rear, Julian J ^a   Harrington, Patrick R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

DAA; FDA; Post Hoc Analysis; Replication

Indexed keywords

ELBASVIR; GRAZOPREVIR; INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; DRUG COMBINATION; ELBASVIR-GRAZOPREVIR DRUG COMBINATION; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; QUINOXALINE DERIVATIVE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG COMBINATION; GENETIC POLYMORPHISM; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BENZOFURANS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; POLYMORPHISM, GENETIC; QUINOXALINES; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85010756634     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.017     Document Type: Article

References (26)

1. 1 Coburn, C.A., Meinke, P.T., Chang, W., et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8 (2013), 1930–1940.
2. 2 Liu, R., Curry, S., McMonagle, P., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59 (2015), 6922–6929.
3. 3 Lahser, F.C., Bystol, K., Curry, S., et al. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 60 (2016), 2954–2964.
4. 4 Harper, S., McCauley, J.A., Rudd, M.T., et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med Chem Lett 3 (2012), 332–336.
5. 5 Summa, V., Ludmerer, S.W., McCauley, J.A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56 (2012), 4161–4167.
6. 6 Buti, M., Gordon, S.C., Zuckerman, E., et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis 62 (2016), 32–36.
7. 7 Lawitz, E., Gane, E., Pearlman, B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1075–1086.
8. 8 Rockstroh, J.K., Nelson, M., Katlama, C., et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2 (2015), e319–e327.
9. 9 Roth, D., Nelson, D.R., Bruchfeld, A., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386 (2015), 1537–1545.
10. 10 Sulkowski, M., Hezode, C., Gerstoft, J., et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1087–1097.
11. 11 Zeuzem, S., Ghalib, R., Reddy, K.R., et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
12. 12 Zepatier (elbasivir and grazoprevir) tablets [package insert], 2016, Merck & Co, Inc, Whitehouse Station, NJ.
13. 13 Bell, A.M., Wagner, J.L., Barber, K.E., et al. Elbasvir/grazoprevir: a review of the latest agent in the fight against hepatitis C. Int J Hepatol, 2016, 2016, 3852126.
14. 14 Kwo, P.Y., Gane, E., Peng, C.Y., et al. Efficacy and safety of grazoprevir/elbasvir +/− ribavirin (RBV) for 12 or 16 weeks in patients with HCV G1, G4, or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial. Gastroenterology 148:Suppl 1 (2015), S1194–S1195.
15. 15 FDA statistical review and evaluation. NDA 208261. Zepatier (MK-5172/MK-8742) (Grazoprevir 100 mg/Elbasvir 50 mg) fixed dose combination. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000StatR.pdf.
16. 16 Bartels, D.J., Sullivan, J.C., Zhang, E.Z., et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87 (2013), 1544–1553.
17. 17 Larrat, S., Vallet, S., David-Tchouda, S., et al. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin. J Clin Microbiol 53 (2015), 2195–2202.
18. 18 Forns, X., Lawitz, E., Zeuzem, S., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146 (2014), 1669–1679 e3.
19. 19 Jacobson, I.M., Dore, G.J., Foster, G.R., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
20. 20 OLYSIO (simeprevir) capsules, for oral use [package insert], 2016, Janssen Therapeutics, Division of Janssen Products, LP, Titusville, NJ.
21. 21 Jacobson, I.M., Asante-Appiah, E., Wong, P., et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 62 (2015), 1393a–1394a.
22. 22 Gower, E., Estes, C., Blach, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:Suppl (2014), S45–S57.
23. 23 Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
24. 24 American Association for the Study of Liver Diseases, Infectious Diseases Society of American. Recommendations for Testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed December 26, 2016.
25. 25 Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151 (2016), 70–86.
26. 26 Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64 (2016), 486–504.